Current Medical Research and Opinion最新文献

{"title":"Integration of administrative claims and clinical data to advance real-world evidence generation in oncology.","authors":"Chi Nguyen, Hanke Zheng, Michael Grabner, John Barron, Ruth Wangia Dixon, Mark Cziraky, Brian Sweet, Nathan Hill","doi":"10.1080/03007995.2025.2482665","DOIUrl":"https://doi.org/10.1080/03007995.2025.2482665","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to evaluate capabilities of the Generating Evidence Excellence (GEx) research environment using Non-Small Cell Lung Cancer (NSCLC) as a use-case.</p><p><strong>Methods: </strong>Patients with incident NSCLC were identified in GEx from 01/01/2015 to 12/31/2019. Two GEx data containers were used: (1) claims from the Healthcare Integrated Research Database (HIRD) linked to clinical data from a Cancer Care Quality Program (CCQP) (HIRD+CCQP); (2) claims data from the HIRD and a second large commercially insured claims dataset (CD2) linked to electronic medical records from IntrinsiQ Specialty Solutions (IQSS) (HIRD+CD2 + IQSS). Patient demographics and all-cause mortality were contrasted with the American Community Survey and the United States Cancer Statistics (USCS) public use database. Descriptive analyses were completed <i>via</i> SAS Enterprise Guide 7.12 and SEER*stat.</p><p><strong>Results: </strong>The study sample comprised of 6,233 (HIRD+CCQP) and 1,176 (HIRD+ CD2 + IQSS) patients with NSCLC. Both GEx data containers had similar patient demographics with a mean age 63 years and 71% White, while 70% of USCS patients were ≥65 years and 85% White. Most patients resided in the South/Midwest regions of the US (74% (HIRD+CCQP) and 86% (HIRD+CD2 + IQSS). Patients in GEx over-represented the working-age group, i.e. 65% were between 18 and 65 years old. Stage IV disease was frequently recorded at diagnosis (59.4% HIRD+CCQP, 44.0% HIRD+CD2 + IQSS, 46.1% USCS). All-cause mortality rate was 38.8 (HIRD+CCQP) and 27.3 (HIRD+CD2 + IQSS) per 100 person-years.</p><p><strong>Conclusions: </strong>The analysis of NSCLC as a use-case demonstrated that GEx is a valuable data ecosystem with a generalizable working-age patient population and comprehensive data to facilitate timely real-world evidence generation in oncology.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-11"},"PeriodicalIF":2.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of functionality, mood, and biopsychosocial status in rheumatic patients with and without self-reported bowel problems and the evaluation of BETY's impact on these factors: a retrospective study.","authors":"Nur Banu Karaca, Aysu Kahraman, Sinan Buran, Orkun Tüfekçi, Fatma Birgül Kumbaroğlu, Zeynep İrem Bulut, Senem Bulut, Aysima Barlak, Atalay Doğru, Umut Kalyoncu, Ali Akdoğan, Şule Apraş Bilgen, Sedat Kiraz, Edibe Ünal","doi":"10.1080/03007995.2025.2486164","DOIUrl":"10.1080/03007995.2025.2486164","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study aimed to evaluate the comparison of functionality, mood, and biopsychosocial status in rheumatic patients with and without self-reported bowel problems and the evaluation of <i>Bilişsel Egzersiz Terapi Yaklaşımı (BETY) - (Cognitive Exercise Therapy Approach in English)</i>'s impact on these factors.</p><p><strong>Methods: </strong>The study included 718 patients with eight different diagnoses of rheumatism. The presence of self-reported bowel problems in rheumatic patients was assessed with item 10 of the BETY-Biopsychosocial Questionnaire (BETY-BQ), functionality with the Health Assessment Questionnaire (HAQ), emotional status with the Hospital Anxiety and Depression Scale (HADS), and biopsychosocial status (BPS) with the BETY-BQ. Sixty-five rheumatic patients were included in BETY group exercise sessions for 3 months, 3 days a week.</p><p><strong>Results: </strong>The rate of self-reporting bowel problems in the total cohort was 61.6%. Among all BPS parameters examined, a significant difference was found in favor of rheumatic individuals who did not report bowel symptoms (<i>p</i> <.005). All patients included in the BETY sessions achieved improvement in all parameters, including bowel symptoms (<i>p</i> <.005).</p><p><strong>Conclusions: </strong>Many patients suffered from bowel problems. The investigated parameters of rheumatic patients with bowel symptoms were negatively affected. BETY improved all parameters, including bowel symptoms. BPS features should be considered in disease management in rheumatic patients reporting bowel problems. BETY should be used as an exercise intervention based on the BPS model in these patients.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-7"},"PeriodicalIF":2.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and mitigation of metabolic bone disease and cardiac adverse events throughout the prostate cancer pathway: clinical review and practical recommendations.","authors":"Lawrence Drudge-Coates, Patrick Davey, Julia Murray, Qizhi Huang, Elena Lopez-Guadamillas, Janet Brown","doi":"10.1080/03007995.2025.2470755","DOIUrl":"https://doi.org/10.1080/03007995.2025.2470755","url":null,"abstract":"<p><p>Some current prostate cancer (PCa) treatment regimens are known to have adverse effects on bone, for example androgen deprivation therapy (ADT), and on cardiovascular health, for example ADT and antiandrogen therapy. Strengthened recommendations for the practical assessment and management of bone and cardiovascular health in men with PCa are needed. This review aims to provide practical guidance for healthcare providers along the continuum of patient care on the management of bone and cardiovascular health in men with PCa undergoing ADT and antiandrogen therapy based on real-world evidence. Evidence was identified by searching PubMed for publications that reported the effects of PCa treatment on bone or cardiovascular health in a real-world setting and were published between January 2017 and August 2023. Review articles were excluded. The evidence identified indicates that ADT decreases bone mineral density (BMD) and increases the risk of osteoporosis and fractures. Bone-protecting agents (BPAs) are effective at improving bone health in patients undergoing ADT and antiandrogen therapy at all stages of the PCa pathway. Despite this, the use and timing of initiation of BPAs are variable. Furthermore, real-world studies have confirmed an association between ADT and cardiovascular risk. As survival outcomes improve, maintenance of bone and cardiovascular health is increasingly important in men with PCa. Risk is a continuous variable that must be assessed throughout the continuum of PCa treatment. Therefore, all men starting ADT should be assessed for bone and cardiovascular risk. Lifestyle adjustments, dietary supplementation and pharmacological intervention may be advised.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-17"},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and eradication effect of vonoprazan and high-dose amoxicillin dual therapy in CagA⁺VacA⁺ <i>Helicobacter pylori</i> infected patients.","authors":"Yongkang Chen, Manli Pan, Kunfeng Yan, Lei Chen, Zhenxing Li, Gongchao Yu, Qingyu Zhang, Xiaorong Dai","doi":"10.1080/03007995.2025.2479791","DOIUrl":"10.1080/03007995.2025.2479791","url":null,"abstract":"<p><strong>Objective: </strong><i>Helicobacter pylori</i> (<i>HP</i>) eradication rates are higher by treated with the potassium-competitive acid blocker vonorasan than with proton pump inhibitors (PPIs). Herein, this study analyzed the clinical efficacy of vonoprazan combined with high-dose amoxicillin for dual therapy in personalized eradication of <i>HP</i>.</p><p><strong>Methods: </strong>This retrospective analysis included 452 patients with type I <i>HP</i> who were assigned to the observation and control groups. Cytotoxin-associated gene A (CagA) and vacuolating cytotoxin A (VacA) antibodies were detected using the <i>H. pylori</i> antibody typing classification assay kit by Western blot. The control group underwent PPI quadruple therapy (oral administration of esomeprazole, amoxicillin, clarithromycin, and colloidal bismuth subcitrate). The observation group was treated with vonoprazan combined with high-dose amoxicillin orally. The clinical efficacy was evaluated after 14 days of treatment, and adverse reactions during treatment were compared. The eradication rates for different <i>HP</i> types in the two groups were detected using a ¹³C-urea breath test.</p><p><strong>Results: </strong>There was no significant difference between the control and observation groups in sex, age, BMI, disease duration, smoking history, or drinking history. The observation group exhibited higher total effective rates and better eradication effects than the control group. The CagA⁺, VacA⁺, or CagA⁺VacA⁺ type patients showed no statistical difference in the incidence of adverse reactions, but the observation group showed a lower total incidence of adverse reactions than the control group.</p><p><strong>Conclusion: </strong>Vonoprazan combined with high-dose amoxicillin has better clinical efficacy and eradication effect for patients with CagA⁺VacA⁺ <i>HP</i>, along with reduced adverse reactions.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-8"},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Author Response for \"Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review\".","authors":"Ignacio J Ansotegui, Jean Bousquet, Giorgio Walter Canonica, Pascal Demoly, Rene Maximiliano Gómez, Eli O Meltzer, Margarita Murrieta-Aguttes, Robert M Naclerio, Nelson Rosario Filho, Glenis K Scadding","doi":"10.1080/03007995.2025.2488951","DOIUrl":"https://doi.org/10.1080/03007995.2025.2488951","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-5"},"PeriodicalIF":2.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy analysis of ciprofol combined with low-dose alfentanil in sedation of patients during transesophageal echocardiography: a randomized double-blind controlled study.","authors":"Lulu Jiang, Pianpian Yan, Shengwen Guo, Jiarong Ma, Yiting Huang, Yanqing Zhou, Liping Wu","doi":"10.1080/03007995.2025.2487102","DOIUrl":"10.1080/03007995.2025.2487102","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the anesthetic effects and safety of ciprofol combined with low-dose alfentanil in sedation of patients during Transesophageal Echocardiography (TEE).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Subjects and methods: &lt;/strong&gt;This is a single-center, prospective, randomized, double-blind controlled clinical trial of 121 patients, aged 18-90 years, classified as ASA II-IV with a body mass index (BMI) ranging from 18-30 kg/m&lt;sup&gt;2&lt;/sup&gt; scheduled for elective outpatient transesophageal echocardiography. These patients were randomly divided into two groups: the ciprofol group and the propofol group. Each patient received a bolus injection of alfentanyl 5 ug/kg intravenously, followed by either 0.5 mg/kg ciprofol or 2 mg/kg propofol over 30 s. The Transesophageal Echocardiography procedure began when the patient's Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) score was ≤1. Intraoperative data such as the lowest blood pressure, lowest oxygen saturation, lowest respiratory rate, occurrence of new arrhythmias, need for assisted ventilation, use of vasopressors and their doses, patient movement, venous injection pain, and cough reflex were recorded. Prior to the recruitment of participants, the study was registered on a clinical research registration website under the title \"Application of Intravenous Cipofol Combined with Low-Dose Alfentanil in Painless Transesophageal Echocardiography in Outpatient Settings,\" with the registration number ChiCTR2400081723.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The incidence of respiratory and circulatory adverse events was significantly lower in the ciprofol group than in the propofol group (30.4% vs. 66.7%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001). The incidence of adverse respiratory events in the ciprofol group was significantly lower than that in the propofol group (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). The incidence rates of respiratory adverse events in the two groups were 18 (32.1%) and 45 (68.2%), respectively, indicating a statistically significant difference (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). The incidence rates of circulatory adverse events were 15 (26.8%) and 33 (50.0%) in the ciprofol and propofol groups, respectively, with a statistically significant difference (&lt;i&gt;p&lt;/i&gt; = 0.015). The rate of vasopressor use (&lt;i&gt;p&lt;/i&gt; = 0.035) and occurrence of systolic blood pressure &lt;90 mmHg (&lt;i&gt;p&lt;/i&gt; &lt; 0.001) were significantly lower in the ciprofol group than in the propofol group. There was no statistically significant difference in the incidence of heart rates less than 40 beats per minute or new-onset arrhythmias between the two groups. Additionally, the incidence of venous injection pain was significantly lower in the ciprofol group than in the propofol group [3 (5.4%) vs. 25 (37.9%), &lt;i&gt;p&lt;/i&gt; &lt; 0.001].&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Ciprofol combined with low-dose alfentanil demonstrated a more favorable safety profile compared to Cpropofol, with significantly reduced rates of adverse events and injection pain.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Registration","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-6"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontiers in bibliometric analysis: the overrepresentation of bibliometric analyses in grey publisher journals.","authors":"Joshua Wang","doi":"10.1080/03007995.2025.2488949","DOIUrl":"https://doi.org/10.1080/03007995.2025.2488949","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-3"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Frontiers in bibliometric analysis: the overrepresentation of bibliometric analyses in grey publisher journals\".","authors":"Jimmy Li, Charles Deacon, Mark Robert Keezer","doi":"10.1080/03007995.2025.2488948","DOIUrl":"https://doi.org/10.1080/03007995.2025.2488948","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-2"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert advice on helping people with obstructive sleep apnea and excessive daytime sleepiness: a plain language summary.","authors":"Joerg S Steier, Richard K Bogan, Irene M Cano-Pumarega, John A Fleetham, Giuseppe Insalaco, Chitra Lal, Teresa Barnes, Jean-Louis Pépin, Winfried J Randerath, Susan Redline, Atul Malhotra","doi":"10.1080/03007995.2025.2476743","DOIUrl":"10.1080/03007995.2025.2476743","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-10"},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis.","authors":"Rika Ohkubo, Junko Hattori","doi":"10.1080/03007995.2025.2470733","DOIUrl":"10.1080/03007995.2025.2470733","url":null,"abstract":"<p><strong>Objective: </strong>Letermovir (LET) is effective for preventing cytomegalovirus infection (CMVi) and CMV disease in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, clinically significant (cs)-CMVi can occur after LET cessation. We retrospectively evaluated the clinical burden of late-onset cs-CMVi in patients who had received LET following allo-HSCT in Japan.</p><p><strong>Methods: </strong>The Japan Medical Data Center health insurance claims database was interrogated for adult patients who had received LET ≤100 days after allo-HSCT (May 28, 2018, to December 31, 2022). Cohorts 1 and 2 (primary analyses) comprised cs-CMVi-positive and -negative patients, respectively, followed for ≥180 days after the first cs-CMVi-related claim; Cohorts 3 and 4 (exploratory analysis) included patients meeting Cohort 1 or 2 criteria, respectively, but without follow-up duration limitation.</p><p><strong>Results: </strong>Data for 155 patients (Cohort 1, <i>n</i> = 47; Cohort 2, <i>n</i> = 108) were analyzed. cs-CMVi rates were higher in patients at high (<i>n</i> = 72) versus low risk (<i>n</i> = 83) of CMVi (43.4% vs 15.3%; <i>p</i> = 0.0003), with no difference in frequency of CMV disease. In Cohort 1, median time from 100 days post-transplantation to first cs-CMVi was 35.0 days. Rates of hospital admissions were higher in Cohort 1 versus Cohort 2 (<i>p</i> = 0.0061), and mean duration of anti-CMV drug prescription was longer in high- versus low-risk patients (<i>p</i> = 0.0024). New-onset graft-versus-host disease occurred ≥101 days post-transplantation in three patients (all Cohort 1).</p><p><strong>Conclusion: </strong>This study demonstrates the great burden of late-onset cs-CMVi in patients after allo-HSCT. Extended LET prophylaxis beyond 100 days post-transplant may benefit especially those at high risk of cs-CMVi.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-11"},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}